CHF Solutions, Inc. Announces Pricing of $18.0 Million Underwritten Public Offering
EDEN PRAIRIE, Minn., Nov. 22, 2017 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (NASDAQ:CHFS) announced today the pricing of an underwritten public offering of Series F convertible preferred stock, together with warrants, for gross proceeds of $18.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions.
The Series F preferred stock is convertible into shares of the company’s common stock at a conversion price of $4.50 per share. Each share of Series F preferred stock will be accompanied by a Series 1 warrant, which expires on the first anniversary of its issuance, to purchase 223 shares of the company’s common stock at an exercise price of $4.50 per share, and a Series 2 warrant, which expires on the seventh anniversary of its issuance, to purchase 223 shares of the company’s common stock at an exercise price of $4.50 per share.
The Series F preferred stock and the warrants are immediately separable and will be issued separately. The closing of the offering is expected to take place on or about November 27, 2017, subject to the satisfaction or waiver of customary closing conditions.
Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), acted as sole book-running manager in connection with the offering.
A total of 18,000 shares of Series F preferred stock convertible into approximately 4 million shares of common stock, and warrants to purchase approximately 8 million shares of common stock will be issued in the offering.
The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-221010), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on November 21, 2017 and an additional registration statement filed pursuant to Rule 462(b), which became effective when filed.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A final prospectus relating to this offering will be filed by CHF Solutions with the SEC. When available, copies of the final prospectus can be obtained at the SEC’s website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 277 Park Avenue, 26th Floor, New York, New York 10172, by calling (212) 409-2000.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company’s objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
For further information, please contact:
Chief Financial Officer
CHF Solutions, Inc.
CHF Solutions, Inc.